Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lyle Breeding

Surgery Brooksville, FL Medical Doctor

NPI 1063625317 CMS profile 93761

11373 Cortez Blvd, Suite 202, Brooksville, FL 34613

Open in the dashboard

General payments

$16,120

138 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lyle Breeding of Brooksville, FL is reported in the CMS Open Payments database as having received $16,120 across 138 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,597 40
2024 General $2,177 23
2023 General $3,772 37
2022 General $730 13
2021 General $143 1
2020 General $141 5
2019 General $562 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lyle Breeding
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Lyle Breeding were reported at $8,597. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Lyle Breeding Surgery median Middle half National median
2019 $562 $253 $82–$1,521 $163
2020 $141 $131 $40–$706 $114
2021 $143 $168 $50–$904 $132
2022 $730 $224 $76–$1,218 $149
2023 $3,772 $253 $82–$1,255 $160
2024 $2,177 $279 $90–$1,381 $164
2025 $8,597 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $7,563 55 payments
  2. Penumbra, Inc. $3,216 17 payments
  3. Silk Road Medical, Inc. $2,696 10 payments
  4. W. L. Gore & Associates, Inc. $1,224 15 payments
  5. Endologix, Inc. $306 2 payments
  6. Medtronic Vascular, Inc. $286 15 payments
  7. Stryker Corporation $167 1 payment
  8. Misonix Inc $143 1 payment
  9. Inari Medical, Inc. $123 5 payments
  10. Cardiovascular Systems Inc. $57 4 payments
  11. Other $339 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,422 24 payments
  2. Food and Beverage $6,698 114 payments
Products named General payments · program years 2019–2025
  1. HawkOne $4,467 4 payments
  2. ENROUTE Transcarotid Stent $2,696 10 payments
  3. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,696 10 payments
  4. Indigo System $2,199 6 payments
  5. ENDURANT IIS $2,045 31 payments
  6. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,432 4 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,432 4 payments
  8. RUBY Coil $513 7 payments
  9. GORE EXCLUDER AAA Endoprosthesis $453 7 payments
  10. Penumbra System $403 3 payments
  11. Other $2,585 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

665

Median for Vascular Surgery: 122

Drug cost

$61,852

Median for Vascular Surgery: $14,135

Branded share of claims

94.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 72 $55,162
Clopidogrel Clopidogrel Bisulfate Brand 558 $5,387
Pentoxifylline Generic 24 $957
Cilostazol Generic 11 $347

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$146,573

Medicare's payments for the services billed

Medicare patients

408

Average age 78

Services billed

1,486

183 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 61%
Chronic kidney disease 53%
COPD 50%
Diabetes 49%
Heart failure 37%
Atrial fibrillation 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record